Weekly Digest – June 2025 Weekly Digest – June 2025 10 June 2025: Kelun-Biotech announces breakthrough therapy designation granted for Sacituzumab tirumotecan (Sac-TMT) in combination with Tagitanlimab in China for certain types of Non-Small Cell Lung Cancer Sichuan Kelun-Biotech’s TROP2-directed […]
Weekly Digest – June 2025 Weekly Digest – June 2025 09 June 2025: DESTINY-Endometrial01 phase 3 Trial of Enhertu initiated as first-line therapy in patients with HER2 expressing primary advanced or recurrent endometrial cancer Daiichi Sankyo and AstraZeneca have initiated […]
Weekly Digest – June 2025 Weekly Digest – June 2025 11 June 2025: Simtra BioPharma solutions and MilliporeSigma announce strategic alliance for antibody drug conjugates drug substance and drug product manufacturing services Simtra BioPharma Solutions and MilliporeSigma (Merck KGaA’s Life […]
Weekly Digest – June 2025 Weekly Digest – June 2025 10 June 2025: Medicovestor and Sanyou Biopharmaceuticals forge strategic partnership to develop first-in-class chemoimmunotherapy antibody-drug conjugates Medicovestor and Sanyou Biopharmaceuticals have formed a strategic partnership to co-develop first-in-class chemoimmunotherapy antibody-drug […]
Weekly Digest – June 2025 Weekly Digest – June 2025 06 June 2025: OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMine Enabling Technologies OBI Pharma and TegMine Therapeutics have entered a Master Services Agreement to collaborate […]
Weekly Digest – June 2025 Weekly Digest – June 2025 09 June 2025: SK plasma enters ADC cancer drug development with AIMEDBIO partnership SK plasma has partnered with AIMEDBIO to co-develop an antibody-drug conjugate (ADC) targeting ROR1, marking SK plasma […]
